Givinostat

N-(4 - (( hydroxyamino ) methyl )-2- naphthalenyl) methyl ester · hydrochloride

Inhibitor of HDAC

Template: Infobox chemical / molecular formula search available

Givinostat is currently undergoing clinical development of potential drug which should be used for the treatment of systemic juvenile idiopathic arthritis and polycythemia. Medicinally it is used as the hydrochloride and is currently in Phase 2 clinical trials.

Pharmacology

Mechanism of Action

Givinostat inhibits histone deacetylase ( HDAC ) and a number of pro-inflammatory cytokines, wherein the tumor necrosis factor - α and the secretion of IL- 1- α, - β and IL-6 is reduced.

By Givinostat the concentration of the Janus kinase 2 is reduced, whereby the abnormal growth of red blood cells is attenuated in polycythemia and an improvement in symptoms is observed.